Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05287958 · ClinicalTrials.gov registry record

Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients

A clinical trial of ALS, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
58
Enrollment target
2
Study locations

NCT05287958: Completed study of ALS, sponsored by Beth Israel Deaconess Medical Center.

NCT05287958 is a study of ALS that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 58 participants, below the 1,034-participant average among 19 other ALS trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05287958, a study of ALS, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
58 participants
Enrollment target
2
Study locations

Study Summary

This is an unblinded pilot study to investigate the technical feasibility of using an electrical impedance tomography device for noninvasive pulmonary function monitoring in ALS patients. The study will enroll patients with ALS in one cohort and healthy volunteers in a second cohort that will both undergo EIT imaging with the investigational device prior to and while performing a standard PFT procedure.

Primary Outcome

A correlation coefficient (-1 to +1) will be used

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST EIT

Study Locations (2)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2021-07-15
Est. Completion 2023-09-20

What the finished NCT05287958 record still lists

NCT05287958 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,034-participant average among 19 other ALS trials with a reported enrollment target (94% lower).

The record links to 1 condition, with ALS appearing as the primary indexed condition, and to 1 intervention - of which EIT is the first listed.

NCT05287958 reports a single indexed study location in Massachusetts, New Hampshire.

Frequently Asked Questions

What is clinical trial NCT05287958 about?

NCT05287958 is a clinical study titled "Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients". This is an unblinded pilot study to investigate the technical feasibility of using an electrical impedance tomography device for noninvasive pulmonary function monitoring in ALS patients. The study will enroll patients with ALS in one cohort and healthy volunteers in a second cohort that will both u...

What is the current status of trial NCT05287958?

This trial is currently completed. The enrollment target is 58 participants. The study started on 2021-07-15. Estimated completion is 2023-09-20.

What conditions does trial NCT05287958 study?

This clinical trial studies the following conditions: ALS.

What interventions are being tested in trial NCT05287958?

The interventions under investigation include: EIT (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05287958?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05287958 being conducted?

This trial has 2 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ALS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05287958's enrollment target sits among peer trials

58 11th of 19 higher than 9 of 19 other ALS trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other ALS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05287958, the US trial registry maintained by the National Library of Medicine. NCT05287958 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.